CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.
Media contact: [email protected]
|
|
|
|
|
51-200 employees
View all CARsgen Therapeutics employees
|
|
|
Biotechnology
|
|
|
$10M–$50M
|
|
|
+86 21 5180 0800
|
|
|
1F, Building 2, No.466, Yindu Rd, Shanghai, Shanghai 200231, CN
|
|
|
2014
|
|
|
Oncology, Oncology, Solid Tumors, Hematologic Malignancies, Solid Tumors, Car T-Cell Therapies
|
Zonghai Li is the CEO of CARsgen Therapeutics. To contact Zonghai Li email at [email protected] or [email protected].
The decision makers in CARsgen Therapeutics are Andy Zang, Baochuan Huang, Cheryl L Askew, etc. Click to Find CARsgen Therapeutics decision makers emails.
CARsgen Therapeutics headquarters is located at 1F, Building 2, No.466, Yindu Rd, Shanghai, Shanghai 200231, CN.
CARsgen Therapeutics generates an estimated $10M–$50M annually, based on industry analysis and publicly available market data.
You can contact CARsgen Therapeutics by calling +86 21 5180 0800.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.